Company TC Biopharm (Holdings) Plc

Equities

TCBP

US87807D4007

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
1.12 ^USD	-2.61%		-1.75%	-64.67%

May. 15	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	MT
May. 15	TC Biopharm Plc Announces Launch of Compassionate Use Program for TCB008	CI

TC BioPharm Limited is a clinical-stage cell therapy company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. Its platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. Its pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications. The Companyâs therapies are focused on leveraging the inherent biological capabilities of GDT cells together with an integrated cell engineering approach.

Number of employees: 41

Managers	Title	Age	Since
Bryan Kobel CEO	Chief Executive Officer	44	21-05-31
Martin Thorp DFI	Director of Finance/CFO	72	14-12-31

Members of the board	Title	Age	Since
Mark Bonyhadi BRD	Director/Board Member	70	22-02-21
Martin Thorp DFI	Director of Finance/CFO	72	14-12-31
Arlene Morris CHM	Chairman	72	22-02-21
Edward Niemczyk BRD	Director/Board Member	44	22-02-21
Anthony Culverwell BRD	Director/Board Member	68	22-02-21
Bryan Kobel CEO	Chief Executive Officer	44	21-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,479,958	2,188,811 ( 88.26 %)	0	74.24 %
Stock B	20	468,179	0	0

Name	Equities	%	Valuation
Csenge Advisory Group LLC 0.4538 %	14,500	0.4538 %	22 765 $
UBS Securities LLC 0.0434 %	1,387	0.0434 %	2 178 $
Steward Financial Group LLC 0.003130 %	100	0.003130 %	157 $
Headlands Technologies LLC 0.003067 %	98	0.003067 %	154 $
Wells Fargo Clearing Services LLC 0.001565 %	50	0.001565 %	79 $

Name	Equities	%	Valuation
Kepos Capital LP -	470,588	-	9 882 $
Nantahala Capital Management LLC -	235,294	-	4 941 $
Virtu Financial LLC -	29,803	-	626 $
Altium Capital Management LP -	18,823	-	395 $
BofA Securities, Inc. -	582	-	12 $

Name	Equities	%	Valuation
Renaissance Capital Partners Ltd. 14.40 %	136,834	14.40 %	50 355 $
MEDINET CO., LTD. 7.737 %	73,500	7.737 %	27 048 $
Mark Edward Randall 1.048 %	9,952	1.048 %	3 662 $
Bryan Kobel 0.2212 %	2,101	0.2212 %	773 $
Ken Randall 0.2114 %	2,008	0.2114 %	739 $
Anthony Culverwell 0.000000 %	0	0.000000 %	- $
Mark Bonyhadi 0.000000 %	0	0.000000 %	- $
Edward Niemczyk 0.000000 %	0	0.000000 %	- $
Arlene Morris 0.000000 %	0	0.000000 %	- $
Martin Thorp 0.000000 %	0	0.000000 %	- $

TC Biopharm (Holdings) Plc

Maxim Park 1 2 Parklands Way

ML1 4WR, Motherwell

+44 14 1433 7557

http://www.tcbiopharm.com

address TC Biopharm (Holdings) Plc(TCBP)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
TC BIOPHARM (HOLDINGS) PLC	-64.67%	3.64M
MODERNA, INC.	+33.63%	50.85B
IQVIA HOLDINGS INC.	-0.09%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	19.13B
BIO-TECHNE CORPORATION	+8.61%	13.05B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.08B

Other Biotechnology & Medical Research